These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 36877916)
1. How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity. Santomasso BD; Gust J; Perna F Blood; 2023 May; 141(20):2443-2451. PubMed ID: 36877916 [TBL] [Abstract][Full Text] [Related]
2. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347 [TBL] [Abstract][Full Text] [Related]
5. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. Freyer CW; Porter DL J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558 [TBL] [Abstract][Full Text] [Related]
6. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Hughes AD; Teachey DT; Diorio C Semin Immunopathol; 2024 Jul; 46(3-4):5. PubMed ID: 39012374 [TBL] [Abstract][Full Text] [Related]
7. Severe persistent neurotoxicity associated with CAR T therapy in children. Andrew EC; Hughes D; Gilsenan M; Mignone C; Khaw SL; Wang SS Br J Haematol; 2023 Nov; 203(4):651-655. PubMed ID: 37528536 [TBL] [Abstract][Full Text] [Related]
8. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. Ruff MW; Siegler EL; Kenderian SS Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871 [TBL] [Abstract][Full Text] [Related]
10. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study. Gutierrez C; Brown ART; May HP; Beitinjaneh A; Stephens RS; Rajendram P; Nates JL; Pastores SM; Dharshan A; de Moraes AG; Hensley MK; Feng L; Brudno JN; Athale J; Ghosh M; Kochenderfer JN; Arias AS; Lin Y; McEvoy C; Mead E; Westin J; Kostelecky N; Mian A; Herr MM Crit Care Med; 2022 Jan; 50(1):81-92. PubMed ID: 34259446 [TBL] [Abstract][Full Text] [Related]
11. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490 [TBL] [Abstract][Full Text] [Related]
13. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S; Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170 [TBL] [Abstract][Full Text] [Related]
14. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome. Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C Clin Neurophysiol; 2024 Jul; 163():132-142. PubMed ID: 38733703 [TBL] [Abstract][Full Text] [Related]